Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Cilomilast

Known as: 4-cyano-4-(3-cyclopentoxy-4-methoxy-phenyl)-cyclohexane-1- carboxylic acid, Cilomilast [Chemical/Ingredient], Cis-4-Cyano-4-(3-(Cyclopentyloxy)-4-Methoxyphenyl)Cyclohexanecarboxylic Acid 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ArifloSB 207499

Broader (3)

Cyclohexanecarboxylic AcidsNitrilesPhosphodiesterase 4 Inhibitors

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2012
Highly Cited
2012
Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
  • P. Schafer
  • Biochemical pharmacology
  • 2012
    • Corpus ID: 19442410
Psoriasis and psoriatic arthritis are common clinical conditions that negatively impact health-related quality of life and are… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Review
2012
Review
2012
The Efficacy and Safety of Cilomilast in COPD
The aim of this review is to present the clinical data on the efficacy and safety of cilomilast in patients with chronic… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • table III
Highly Cited
2007
Highly Cited
2007
Roflumilast inhibits leukocyte‐endothelial cell interactions, expression of adhesion molecules and microvascular permeability
The present study addressed the effects of the investigational PDE4 inhibitor roflumilast on leukocyte‐endothelial cell… Expand
Review
2005
Review
2005
Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease
Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad… Expand
Highly Cited
2003
Highly Cited
2003
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.
Cilomilast (Ariflo), a new oral phosphodiesterase-4 selective inhibitor, improves lung function in chronic obstructive pulmonary… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 4
Highly Cited
2003
Highly Cited
2003
Effect of cilomilast (Ariflo) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD
Background: Inflammation in chronic obstructive pulmonary disease (COPD) is characterised by increased neutrophilic infiltration… Expand
Highly Cited
2001
Highly Cited
2001
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study
BACKGROUND Chronic obstructive pulmonary disease (COPD) is a common, progressive respiratory disease that causes great morbidity… Expand
Highly Cited
2001
Highly Cited
2001
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
From a series of benzamide derivatives, roflumilast (3-cyclo-propylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Review
2001
Review
2001
Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
  • M. Giembycz
  • Expert opinion on investigational drugs
  • 2001
    • Corpus ID: 21654297
Cilomilast (Ariflo™ , SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE